Abstract
Purpose :
To describe cases of visually significant vitreous hemorrhage (VH) following dexamethasone (DEX) intravitreal implant in our practice and present two cases which did not clear spontaneously and eventually required surgical intervention, as well as a case of VH and hypotony following DEX implant. We also describe and illustrate a new injection technique in order to minimize incidence of these complications in the future.
Methods :
Restrospective case series. In addition, new injection technique is described.
Results :
In our practice, the overall incidence of VH was 1.7% (8/467 injections) and those that required surgical intervention was 0.4% (2/467) over a 10 year period, from June 2010 to June 2020. 75% (6/8) VH resolved spontaneously over time, without surgical intervention.
Conclusions :
We propose that after the DEX applicator is in the eye, the needle should be pointed up until it is parallel to the IOL. Usually at this point, it can be directly visualized, when standing at the patient's head. The depressor is then slowly depressed and then the DEX implant can be directly visualized slowly entering the eye.
This is a 2021 ARVO Annual Meeting abstract.